PatientsVille.com Logo

STOMATITIS and OMEPRAZOLE

PatientsVille

STOMATITIS Symptoms and Causes

Canker sores are small, round sores in your mouth. They can be on the inside of your cheek, under your tongue, or in the back of your throat. They usually have a red edge and a gray center. They can be quite painful. They are not the same as cold sores, which are caused by herpes simplex.

Canker sores aren't contagious. They may happen if you have a viral infection. They may also be triggered by stress, food allergies, lack of vitamins and minerals, hormonal changes or menstrual periods. In some cases the cause is unknown.

In most cases, the sores go away by themselves. Some ointments, creams or rinses may help with the pain. Avoiding hot, spicy food while you have a canker sore also helps.

Check out the latest treatments for STOMATITIS

STOMATITIS treatment research studies

OMEPRAZOLE clinical trials, surveys and public health registries


Find Drug Side Effect reports



OMEPRAZOLE Side Effects

Hypomagnesaemia (418)
Diarrhoea (311)
Hypocalcaemia (288)
Nausea (285)
Renal Failure Acute (241)
Vomiting (240)
Dyspnoea (225)
Dizziness (205)
Gastrooesophageal Reflux Disease (191)
Fatigue (168)
Pain (164)
Abdominal Pain (163)
Headache (157)
Malaise (155)
Dyspepsia (152)
Rash (148)
Asthenia (146)
Fall (137)
Abdominal Pain Upper (133)
Confusional State (130)
Hypokalaemia (126)
Condition Aggravated (125)
Pruritus (120)
Arthralgia (118)
Anxiety (117)
Tubulointerstitial Nephritis (116)
Pyrexia (116)
Hyponatraemia (115)
Product Substitution Issue (113)
Paraesthesia (112)
Weight Decreased (111)
Muscle Spasms (109)
Anaemia (106)
Decreased Appetite (104)
Chest Pain (100)
Dysphagia (93)
Convulsion (88)
Dehydration (86)
Depression (84)
Cough (84)
Lethargy (79)
Urticaria (78)
Constipation (78)
Muscular Weakness (78)
Pain In Extremity (76)
Myalgia (76)
Tetany (73)
Tremor (73)
Oedema Peripheral (73)
Pneumonia (72)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I started taken omeprazole. I ran out of my Nexum well I started itching really bad as it I had bug bites believe me I will never uses this again. I've never had reaction to a med before

I stopped taking Omeprazole 20mg after 4 days because of a side effect, strong palpitations most of the time; I stopped taking them a week ago and still have the palpitations. It's very scary........

I am experiencing itching on my arms, rashes on arms and shoulders, hoarseness, slight dizziness, trouble sleeping and mild headaches. I was prescribed this medication for treatment of bloating caused by my hiatal hernia but can

After 2 weeks skin burning on chest and back nevrous sytoms O:-) :'(

After the 1st week I suffered from severe dizzyness, nausea and headaches. Vomited everything I ate. Yet around 5pm I would always feel relatively human again.

An update, It has only been 3 days & my arm pain has gone!!, for anybody suffering similar symptoms to mine this is what i done...1.STOP taking omeprazole. 2. buy plenty bottled water & drink upto 6 bottles per day. 3 eat healthy (det

Been taking omeprazole for 6 years. during that time diagnosed with osteoporsis. after reading about this seems any proton pump inhibitor can cause. so angry with doctor. looking now for new drug, severe gerd and hiatal hernia.

Both arms , upper arm muscle weakness and pain, , dosage 40mg twice a day

By day 4 severe leg pain, joing pain and cramping and prior never had this pain. All my muscles appear to be tighting up and going to discontinue this ASAP. I guess I am having a very rare reation to Prilosec.

Could the omeprazole be causing sking irritation and the spots that have appeared in my scalp, i was much better when i was taking lanzoperazole

STOMATITIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies
Condition: Oral Mucositis
Interventions: Drug: rhEGF + povidone iodine, chlorhexidine, & nystatin;   Drug: Placebo + povidone iodine, chlorhexidine, & nystatin
Outcome Measures: Incidence of oral mucositis of grade 2 or higher (NCI CTCAE 3.0);   Adverse events;   Day of onset and duration of oral mucositis of grade 2 or higher (NCI CTCAE 3.0);   Incidence, day of onset, and duration of oral mucositis of grade 3 or higher (NCI CTCAE 3.0);   Incidence, day of onset, and duration of oral mucositis of grade 2 or higher (WHO);   Incidence, day of onset, and duration of oral mucositis of grade 3 or higher (WHO);   Incidence, day of onset, and duration of oral mucositis of grade 4 or higher (WHO);   OMDQ (oral mucositis daily questionnaire) score during treatment
2 Recruiting Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer
Condition: Oral Mucositis
Interventions: Device: Low intensity laser for oral mucositis;   Device: Low intensity laser for oral mucositis switch off
Outcome Measures: Evaluate the effectiveness of using low-intensity laser compared with placebo as preventive and therapeutic intervention of oral mucositis induced by radiation therapy and chemotherapy.;   Evaluate the effectiveness of using low level laser compared with placebo in the prevention of onset of oral mucositis induced by treatment of head and neck QRT.;   Evaluate the effectiveness of the use of low laser intensity versus placebo in improving the healing of oral mucositis induced by treatment of head and neck QRT.;   Evaluate the effectiveness of using low level laser compared with placebo in reducing pain during and after cancer treatment.;   Evaluate the effectiveness of using low level laser compared with placebo in analgesic use during and after cancer treatment.;   Assess the intervention tolerance and side effects of it.
3 Recruiting Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis
Condition: Recurrent Aphthous Stomatitis
Intervention: Drug: vitamin B12 treatment
Outcome Measures: frequency of recurrent aphthous Stomatitis (RAS);   severity of recurrent aphthous Stomatitis (RAS)
4 Not yet recruiting Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Oral Complications;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: mucoadhesive oral wound rinse;   Other: laboratory biomarker analysis
Outcome Measures: Rate of grades 1-4 Stomatitis assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03;   Rate of grade 3/4 Stomatitis assessed using CTCAE version 4.03
5 Recruiting Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer
Conditions: Head and Neck Cancer;   Oral Mucositis
Interventions: Dietary Supplement: Grape extract;   Drug: Lortab, Fentanyl patch, mouthwash
Outcome Measures: Pain caused by oral mucositis;   Level of immune biomarkers in blood;   Level of immune biomarkers in mucosal tissue
6 Recruiting Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis
Condition: Nasopharyngeal Cancers
Interventions: Drug: rhGM-CSF;   Drug: Compound Vitamin B12
Outcome Measures: The incidence of grade II and less oral mucositis at the end of treatment;   Pain;   Cumulative incidence and time of grade III and more oral mucositis;   Dysphagia;   Tumor response to chemoradiotherapy
7 Unknown  Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
Condition: Oral Mucositis
Intervention: Drug: IZN-6N4
Outcome Measures: Proportion of WHO score 3-4 Oral Mucositis at a Cumulative Radiation Dosage of 50 Gy in the active and Placebo Groups;   Incidence of grade 2-3-4 Oral Mucositis as measured by the WHO scale at increasing increments of cumulative radiation exposure
8 Recruiting Viral Therapy in Treating Patient With Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Recurrent Adult Primary Liver Cancer
Interventions: Biological: recombinant vesicular Stomatitis virus expressing interferon beta;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: MTD, defined as the highest dose at which no more than 1/6 patients experiences dose limiting toxicities (DLT), graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Incidence of adverse events, graded according to NCI CTCAE version 4.0;   Best tumor response, defined as the best objective status recorded among patients with measurable disease at baseline using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;   Overall survival
9 Recruiting Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis
Condition: Oral Mucositis
Interventions: Drug: Clonidine Lauriad® 50µg;   Drug: Clonidine Lauriad® 100µg;   Drug: Placebo Lauriad®
Outcome Measures: Percentage of patients with an oral mucositis score≥ 3 using the WHO scale at cumulative radiation dose of 50 Gy;   Percentage of patients with an oral mucositis score≥ 3 using the WHO scale at cumulative radiation doses of 40 Gy and 60 Gy
10 Unknown  The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients
Condition: Stomatitis
Interventions: Drug: rhEGF;   Drug: Placebo
Outcome Measures: Incidence of severe oral mucositis (RTOG garde 3 or 4);   Incidence and duration of ≥ grade 2, 3 (RTOG scale) oral mucositis;   Incidence and duration of ≥ grade 2, 3 (WHO scale) oral mucositis
11 Recruiting Caphosol in Oral Mucositis Due to Targeted Therapy
Conditions: Oral Mucositis;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Gastrointestinal Stromal Tumors
Interventions: Other: supersaturated calcium-phosphate rinse;   Other: sodium chloride 0.9 %
Outcome Measures: Assess the severity of patient-reported oral adverse events as determined by the change in the VHNSS2.0 score 3 times a week, from onset of oral adverse events during the active oral rinse period with Caphosol versus NaCl 0.9%;   Determine the decrease in grade of oral adverse events as measured by the NCI-CTCAE v4.0 once a week, during a 2 week treatment with Caphosol oral rinse versus NaCl 0.9% oral rinse, 4 times daily, 2 minutes with 30 ml solution;   Assess the incidence of dose delay or dose interruption, dose reduction and discontinue treatment owing to oral burden due to targeted anticancer therapy during the active oral rinse period, once a week;   To correlate the incidence of oral mucositis with: grade ≥ 2 hand-foot skin reaction (HFSR), and grade ≥ 2 papulopustular eruption (PPE) with all agents as measured by the NCI-CTCAE v4.0, during the active oral rinse period, once a week;   Side Study: Explorative analysis of polymorphism in genes encoding for pharmacokinetic and pharmacodynamic variables related to the pharmacodynamics of the TKIs
12 Recruiting Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
Conditions: Mucositis;   Multiple Myeloma
Interventions: Drug: 0.9% Sodium Chloride irrigation solution;   Other: Cryotherapy (ice chips);   Device: Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse
Outcome Measure: Incidence of severe oral mucositis
13 Recruiting A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation
Condition: Oral Mucositis in Patients Undergoing HSCT
Interventions: Drug: Lactobacillus CD 2;   Other: Placebo
Outcome Measures: Incidence of mucositis grade(Common Terminology Criteria of Adverse Events (CTCAE) and World health Organization (WHO);   Incidence,duration and time period of mucositis Common Terminology Criteria of Adverse Events (CTCAE) and World health Organization (WHO)
14 Recruiting Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Condition: Advanced Breast Cancer
Intervention: Drug: Dexamethasone based mouth
Outcome Measures: Incidence of Grade ≥ 2 Stomatitis at 2 months;   Average time to resolution
15 Unknown  Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients
Condition: Oral Mucositis
Intervention: Other: no intervention study
Outcome Measure: incidence and severity of oral mucositis
16 Recruiting Herbal Mouthrinse for Oral Mucositis Study
Condition: Oral Mucositis
Interventions: Drug: Neem Mouthrinse;   Drug: Placebo Mouthrinse
Outcome Measures: Maximum change in mouth and throat soreness (MTS) score from baseline through weeks of radiation therapy using the MTS question of the modified Oral Mucositis Daily Questionnaire.;   Differences in quality of life between the two study groups measured by quality of life questionnaire.
17 Recruiting Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
Conditions: Oral Mucositis;   Pain;   Infection;   Nutrition Aspect of Cancer
Intervention: Other: Cryotherapy
Outcome Measures: Mucositis grade - WHO Oral Toxicity Scale;   Mucositis grade - Children´s International Mucositis Evaluation Scale (ChiMES);   Pain - Childrens Hospital Eastern Ontario Pain Scale (CHEOPS);   Mouth Pain;   Emotional and Psychological status
18 Recruiting A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: Placebo;   Drug: 2% Rebamipide liquid;   Drug: 4% Rebamipide liquid
Outcome Measures: Incidence of oral mucositis graded as severe or worse.;   Onset time, duration and incidence of oral mucositis.;   The maximum severity grade for oral mucositis.;   Quality of life
19 Recruiting The Effect of Honey on Xerostomia and Oral Mucositis
Condition: Head and Neck Cancer
Interventions: Dietary Supplement: Honey mouthwash;   Other: Normal Saline
Outcome Measures: Change from baseline in Xerostomia grades;   Change from baseline in oral mucositis grades;   Changes in the General satisfaction of comfort;   Change in baseline weight in one month
20 Unknown  Dexpanthenol Mouthwash to Treat Oral Mucositis
Condition: Oral Mucositis (Ulcerative) Due to Radiation
Intervention: Drug: Dexpanthenol
Outcome Measure: reduction of intensity of mucositis